Squamous Cell Carcinoma of the Lung
📧 Sign up to get email alerts when something new happens for Squamous Cell Carcinoma of the Lung.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-12-10Clinical Trial Update: Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma [Phase 2]
A Phase 2 neoadjuvant trial of nimotuzumab with gemcitabine and carboplatin for unresectable Stage III squamous cell lung carcinoma has been…
-
CLINICAL_TRIALS withdrawal · 2019-02-01Clinical Trial Update: Photodynamic Therapy for the Prevention of Lung Cancer [Phase 2, Phase 3]
Phase 2/3 clinical trial investigating photodynamic therapy for prevention of lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-28Clinical Trial Update: Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer [Phase 1, Phase 2]
The clinical trial evaluating Sym004 in combination with nivolumab for EGFR-amplified squamous non-small cell lung cancer has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2016-11-04Clinical Trial Update: A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease [Phase 1]
A Phase 1 study of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel for squamous non-small cell lung ca…
-
CLINICAL_TRIALS withdrawal · 2015-10-30Clinical Trial Update: Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial evaluating the combination of selinexor and docetaxel for recurrent or metastatic squamous cell lung cancer has been withdr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-03-19Clinical Trial Update: Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC [Phase 1]
A Phase I study evaluating active breathing control with simultaneous boost for non-small cell lung cancer has been withdrawn.